CLINICAL TRIALS AND OBSERVATIONS UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia
نویسندگان
چکیده
Patel, Elisabeth Paietta, Martin S. Tallman and Anthony H. Goldstone Hillard Lazarus, Selina M. Luger, David I. Marks, Andrew K. McMillan, Anthony V. Moorman, Bella Adele K. Fielding, Jacob M. Rowe, Georgina Buck, Letizia Foroni, Gareth Gerrard, Mark R. Litzow, lymphoblastic leukemia regimen enhances long-term outcomes in Philadelphia positive acute UKALLXII/ECOG2993: addition of imatinib to a standard treatment
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993
1University College London, London, United Kingdom; 2Rambam Medical Center and Technicon, Israel Institute of Technology, Haifa, Israel; 3Clinical Trial Service Unit, Oxford, United Kingdom; 4Northern Institute for Cancer Research, Newcastle University, Newcastle, United Kingdom; 5Bristol Haematology and Oncology Centre, Bristol, United Kingdom; 6Nottingham University, Nottingham, United Kingdo...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early molecular response to posttransplantation imatinib determines outcome in MRD Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)
In adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph ALL), minimal residual disease (MRD) after stem cell transplantation (SCT) is associated with a relapse probability exceeding 90%. Starting imatinib in the setting of MRD may decrease this high relapse rate. In this prospective multicenter study, 27 Ph ALL patients received imatinib upon detection of MRD after SCT. Bcr-a...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome–positive acute lymphoid leukemias
The translocation (9;22) gives rise to the p190Bcr-Abl and p210Bcr-Abl tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph ) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We c...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)
The Abl kinase inhibitor imatinib mesylate (STI571) has significant and rapid antileukemic activity in Philadelphia chromosome/Bcr-Abl–positive acute lymphoblastic leukemia (Ph ALL) but such activity is usually of short duration except for a small proportion of patients. To determine the prognostic significance of early Bcr-Abl levels and changes in peripheral blood (PB) and bone marrow (BM), s...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph ALL)
The best strategy for incorporating imatinib in front-line treatment of Ph acute lymphoblastic leukemia (ALL) has not been established. We enrolled 92 patients with newly diagnosed Ph ALL in a prospective, multicenter study to investigate sequentially 2 treatment schedules with imatinib administered concurrent to or alternating with a uniform induction and consolidation regimen. Coadministratio...
متن کامل